Back

Design and rationale of the efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled trial (EDIT-CAS).

30 August 2025 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: A deep dive into coronary physiology Coronary Vasoreactivity Testing ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Ms Caia Crooijmans

Radboud University Medical Centre, Nijmegen (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Minimum lumen area indexed to left ventricular mass to identify functionally-significant left main coronary stenoses: the ARMYDA FINISH study
Doctor L. Grisafi (Novara, IT)
Abstract Slides Video
Presentation thumbnail
Invasive coronary function testing changes management in patients with ANOCA - an analysis of a multicentre experience in the UK
Doctor J. Abramik (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Coronary flow indices after percutaneous coronary intervention in relation to major adverse cardiovascular events at long-term follow-up in chronic coronary syndrome
Mr A. Fedchenko (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Fractional flow reserve in multivessel disease: impact of coronary revascularization on the hemodynamic relevance of parallel stenoses
Mr J. Altstidl (Erlangen, DE)
Abstract Slides Video
Presentation thumbnail
Invasive assessment of coronary microvascular dysfunction in patients with angina and unobstructed coronary arteries (ANOCA) - Comparison of Doppler- and Thermodilution derived measurements
Miss L. Lauinger (Frankfurt Am Main, DE)
Abstract Slides Video

Access the full session

Session thumbnail
A deep dive into coronary physiology

The Event

Event poster

ESC Congress 2025

30 August 2025 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Zibotentan in microvascular angina: a randomized, placebo-controlled, crossover trial
thumbnail
Congress Presentation
DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
thumbnail
Congress Presentation
MACROS-2: RCT of ESC 0/1 versus 0/3 hour ADP for suspected ACS

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources